Greenwich LifeSciences In... (GLSI)
Greenwich LifeSciences Statistics
Share Statistics
Greenwich LifeSciences has 13.27M shares outstanding. The number of shares has increased by 2.06% in one year.
| Shares Outstanding | 13.27M |
| Shares Change (YoY) | 2.06% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 8.84% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 974 |
| FTD / Avg. Volume | 1.35% |
Short Selling Information
The latest short interest is 910.68K, so 6.86% of the outstanding shares have been sold short.
| Short Interest | 910.68K |
| Short % of Shares Out | 6.86% |
| Short % of Float | 14.48% |
| Short Ratio (days to cover) | 4.12 |
Valuation Ratios
The PE ratio is -9.26 and the forward PE ratio is null. Greenwich LifeSciences's PEG ratio is -0.12.
| PE Ratio | -9.26 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 57.68 |
| P/FCF Ratio | -20.11 |
| PEG Ratio | -0.12 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Greenwich LifeSciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.62, with a Debt / Equity ratio of 0.
| Current Ratio | 2.62 |
| Quick Ratio | 2.62 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-3,947,202.25 |
| Employee Count | 4 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -28.66% in the last 52 weeks. The beta is 3.38, so Greenwich LifeSciences's price volatility has been higher than the market average.
| Beta | 3.38 |
| 52-Week Price Change | -28.66% |
| 50-Day Moving Average | 10.63 |
| 200-Day Moving Average | 12.9 |
| Relative Strength Index (RSI) | 49.52 |
| Average Volume (20 Days) | 72,288 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -16.01M |
| Net Income | -15.79M |
| EBITDA | -16.01M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.21 |
Balance Sheet
The company has 4.09M in cash and 0 in debt, giving a net cash position of 4.09M.
| Cash & Cash Equivalents | 4.09M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -66.15M |
| Total Assets | 4.09M |
| Working Capital | 2.53M |
Cash Flow
In the last 12 months, operating cash flow was -7.27M and capital expenditures 0, giving a free cash flow of -7.27M.
| Operating Cash Flow | -7.27M |
| Capital Expenditures | n/a |
| Free Cash Flow | -7.27M |
| FCF Per Share | -0.56 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GLSI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for GLSI is $39, which is 290.8% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $39 |
| Price Target Difference | 290.8% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | 15.07 |
| Piotroski F-Score | 2 |